LoBue C, Wadsworth H, Wilmoth K, Clem M, Jr Hart J, Womack KB
Diabetologia 59(7):14121421 Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N (2018) Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)
Loerch PM, Lu T, Dakin KA, Vann JM, Isaacs A, Geula C et al (2008)
Personalized prescription GLP-1 medication From $199
The 23andme raw data can be run through 3rd party applications to get SNP reports
The latest findings contribute to the growing evidence that GLP-1 receptor agonists will continue to have a place in healthcare through prevention of progression of diabetes, CVD and kidney disease